Evidence map›Paper›PMID 37233882›Full record

ArticleGeroScience2024

Low circulating adropin concentrations predict increased risk of cognitive decline in community-dwelling older adults.

Geetika Aggarwal, John E Morley, Bruno Vellas, Andrew D Nguyen, Andrew A Butler, MAPT/DSA Group

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in GeroScience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00672685 (Assessment of the Efficacy of Omega-3 Fatty Acids Supplementation, Multi-domain Intervention or Their Combination on the Change of Cognitive Functions in Frail Elderly Subjects), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00672685 nacompletednot on this map

Assessment of the Efficacy of Omega-3 Fatty Acids Supplementation, Multi-domain Intervention or Their Combination on the Change of Cognitive Functions in Frail Elderly Subjects

TypeinterventionalSponsorUniversity Hospital, ToulouseRan2008 to 2014Enrolled1,680ConditionsFrail Elderly SubjectsArmsomega-3, multi-domain intervention, Placebo
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 14 institutions in 4 countries.

Geetika AggarwalHenry and Amelia Nasrallah Center for Neuroscience, Saint Louis University, St. Louis, MO, USA.
John E MorleyDivision of Geriatric Medicine, Department of Internal Medicine, Saint Louis University School of Medicine, St. Louis, MO, USA.
Bruno VellasGérontopôle de Toulouse, Institut du Vieillissement, Centre Hospitalo-Universitaire de Toulouse, 37 Allées Jules Guesdes, 31000, Toulouse, France.
Andrew D Nguyen *Henry and Amelia Nasrallah Center for Neuroscience, Saint Louis University, St. Louis, MO, USA. andy.d.nguyen@health.slu.edu.ORCID 0000-0002-9492-9472
Andrew A Butler *Henry and Amelia Nasrallah Center for Neuroscience, Saint Louis University, St. Louis, MO, USA. Andrew.butler@health.slu.edu.ORCID 0000-0001-7196-0170
MAPT/DSA Group
Centre Hospitalier Universitaire de Toulouse · FRCentre de recherche en Epidémiologie et Santé des Populations · FRWashington University in St. Louis · USCHU Dijon Bourgogne · FRInstitut Universitaire de Gériatrie de Montréal · CALaboratoire d'Aérologie · FRUniversité de Bordeaux · FRCentre National de la Recherche Scientifique · FRLaboratoire de Génie des Procédés – Environnement – Agro-alimentaire · FRLaboratoire Eau, Environnement et Systèmes Urbains · FRNVH Medicinal (France) · FRThe University of Western Australia · AUUniversité Paris Cité · FRUniversity of Washington · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The secreted peptide adropin is highly expressed in human brain tissues and correlates with RNA and proteomic risk indicators for dementia. Here we report that plasma adropin concentrations predict risk for cognitive decline in the Multidomain Alzheimer Preventive Trial (ClinicalTrials.gov Identifier, NCT00672685; mean age 75.8y, SD = 4.5 years, 60.2% female, n = 452). Cognitive ability was evaluated using a composite cognitive score (CCS) that assessed four domains: memory, language, executive function, and orientation. Relationships between plasma adropin concentrations and changes in CCS (∆CCS) were examined using Cox Proportional Hazards Regression, or by grouping into tertiles ranked low to high by adropin values and controlling for age, time between baseline and final visits, baseline CCS, and other risk factors (e.g., education, medication, APOE4 status). Risk of cognitive decline (defined as a ∆CCS of - 0.3 or more) decreased with increasing plasma adropin concentrations (hazard ratio = 0.873, 95% CI 0.780-0.977, P = 0.018). Between adropin tertiles, ∆CCS was significantly different (P = 0.01; estimated marginal mean ± SE for the 1st to 3rd tertile, - 0.317 ± 0.064; - 0.275 ± 0.063; - 0.042 ± 0.071; n = 133,146, and 130, respectively; P < 0.05 for 1st vs. 2nd and 3rd adropin tertiles). Normalized plasma Aß

Indexed as

Alzheimer DiseaseCognitive DysfunctionAgedCognitionFemaleHumansIndependent LivingMaleProteomicsAdropinAgingCognitive declineDementiaPlasma biomarkers

Identifiers

PMID37233882
PMCPMC10828274
OpenAlexW4378347872

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.